References
- Muthu MS , SinghS. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine (Lond.)4(1) , 105–118 (2009).
- Muthu MS , RajeshCV, MishraA, SinghS. Stimulus responsive targeted nanomicelles for effective cancer therapy. Nanomedicine (Lond.)4(6) , 657–667 (2009).
- McCarthy JR . The future of theranostic nanoagents. Nanomedicine (Lond.)4(7) , 693–695 (2009).
- Bawa R . Will the nanomedicine ‘patent land grab‘ thwart commercialization? Nanomedicine (Lond.)1(4) , 346–350 (2005).
- Bawarski WE , ChidlowskyE, BharaliDJ, MousaSA. Emerging nanopharmaceuticals. Nanomedicine4(4) , 273–282 (2008).
- Muthu MS , FengSS. Nanopharmacology of liposomes developed for cancer therapy. Nanomedicine (Lond.)5(7) , 1017–1019 (2010).
- Ying X , WenH, Lu W-L et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J. Control. Rel.141(2) , 183–192 (2010).
- Ying X , WenH, Yao H-J et al. Pharmacokinetics and tissue distribution of dual-targeting daunorubicin liposomes in mice. Pharmacology87 , 105–114 (2011).
- Bawa R . Patents and nanomedicine. Nanomedicine (Lond.)2(3) , 351–374 (2007).
- Wilson B . Therapeutic compliance of nanomedicine in Alzheimer‘s disease. Nanomedicine (Lond.)6(7) , 1137–1139 (2011).
- Muthu MS , FengSS. Targeted nanomedicine for detection and treatment of circulating tumor cells. Nanomedicine (Lond.)6(4) , 579–581 (2011).
▪ Patents
- Chen I, Jie L, Roa T, Wilson P: US0034735 (2010).
- Natarajan A, Denardo, SJ, Denardo GL et al.: US0179303 (2010).
- Chen M-C, Tu H, Sung H-W et al.: US0160078 (2008).
- Oyelere A, El-sayed M, Dreaden EC et al.: US0077581 (2011).
- Desai NP, Soon-Shiong P: US0112077 (2010).
- Panyam J, Patil Y, Khdair A: US0015050 (2010).
- Labhasetwar VD, Sahoo SK: US0015051 (2010).
- Pitcovski J, Shahar E, Gorodetsky R: US0213629 (2011).